博济医药科技股份有限公司 关于非经营性资金占用及其他关联 资金往来情况的专项审核说明 司农专字[2025]24008270062 号 目 录 报告正文………………….………………………………..1-2 附件一： 博济医药科技股份有限公司 2024 年度非经营性资金占用 及其他关联资金往来情况汇总表………………………...3-4 关于博济医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 本专项说明仅供博济医药年度报告披露之目的使用，不得用作任何其他目的。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金往 来、对外担保的监管要求》的要求及深圳证券交易所《深圳证券交易所创业板上市 公司自律监管指南第 1 号——业务办理》的规定，博济医药管理层编制了后附的 《博济医药科技股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情 况汇总表》（以下简称汇总表）。如实编制和对外披露汇总表并保证其真实、准确、 完整是博济医药管理层的责任。 我们对汇总表所载信息与本所审计博济医药 2024 年度财务报表时所复核的会 计资料和经审计的财务报表的相关内容进行了核对，在所有重大方面 ...

北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 2023 年度限制性股票激励计划 首次授予部分第二个解除限售期及预留授予部分 第一个解除限售期解除限售条件成就、 首次授予部分第二个归属期归属条件成就的 法 律 意 见 书 北京市康达（广州）律师事务所 BEIJING KANGDA LAW FIRM Guangzhou Branch 地址：广州市珠江新城珠江东路 32 号利通广场 29 层 邮政编码：510630 电话：020-37392666 传真：020-37392826 1 北京市康达（广州）律师事务所 法律意见书 关于博济医药科技股份有限公司 2023 年度限制性股票激励计划 首次授予部分第二个解除限售期及预留授予部分 第一个解除限售期解除限售条件成就、 首次授予部分第二个归属期归属条件成就的 法 律 意 见 书 致：博济医药科技股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受博济医药科技股份有 限公司（下称"博济医药"或"公司"）委托，根据《公司法》、《证券法》等法 律、法规和规范性文件的有关规定，按照律师行业公认的业务标准、道德规范 ...

2024 年度募集资金存放与使用情况的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为博 济医药科技股份有限公司（以下简称"博济医药"或"公司"）的保荐机构， 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关法律法规及规范性文件的要 求，对博济医药 2024 年度募集资金存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 （一）实际募集金额及资金到位情况 广发证券股份有限公司关于博济医药科技股份有限公司 （一）募集资金的管理情况 为了规范募集资金的管理和使用，保护投资者权益，公司依照《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等有关法律、法规的规定，结合公司的实际情况，制 定了《募集资金管理制度》，对募集资金的存储、使用、用途变更及监督管理作 出了明确规定。 公司对募集资金实行专户存储，并对募集资金的使用执行严格的审批程序， 以保证专款专用。 2021 年，公司 ...

北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 2022 年股票期权激励计划第三个行权期 1 行权条件成就的 法 律 意 见 书 北京市康达（广州）律师事务所 BEIJING KANGDA LAW FIRM Guangzhou Branch 地址：广州市珠江新城珠江东路 32 号利通广场 29 层 邮政编码：510630 电话：020-37392666 传真：020-37392826 北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 2022 年股票期权激励计划第三个行权期 行权条件成就的 法 律 意 见 书 致：博济医药科技股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受博济医药科技股份有 限公司（下称"博济医药"或"公司"）委托，担任博济医药 2022 年股票期权激 励计划项目的专项法律顾问，现本所律师根据《中华人民共和国公司法》、《中华 人民共和国证券法》等法律、法规和规范性文件的有关规定，按照律师行业公认 的业务标准、道德规范和勤勉尽责精神，就博济医药 2022 年股票期权激励计划 ...

北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 2024 年限制性股票激励计划 第一个归属期归属条件成就的 法 律 意 见 书 北京市康达（广州）律师事务所 BEIJING KANGDA LAW FIRM Guangzhou Branch 地址：广州市珠江新城珠江东路 32 号利通广场 29 层 邮政编码：510630 电话：020-37392666 传真：020-37392826 1 北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 2024 年限制性股票激励计划 第一个归属期归属条件成就的 法 律 意 见 书 致：博济医药科技股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受博济医药科技股份有 限公司（下称"博济医药"或"公司"）委托，根据《公司法》《证券法》等法律、 法规和规范性文件的有关规定，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神就博济医药 2024 年限制性股票激励计划所涉及的相关事项出具法律意 见。为出具本法律意见书，本所及本所律师声明如下： 一、本所及本所律师依据《 ...

博济医药科技股份有限公司 2024 年度审计报告 司农审字[2025]24008270037 号 目 录 | 审计报告………………………………………………… | 1-6 | | --- | --- | | 合并资产负债表………………………………………… | 1 | | 合并利润表……………………………………………… | 2 | | 合并现金流量表………………………………………… | 3 | | 合并所有者权益变动表………………………………… | 4-5 | | 母公司资产负债表……………………………………… | 6 | | 母公司利润表…………………………………………… | 7 | | 母公司现金流量表……………………………………… | 8 | | 母公司所有者权益变动表……………………………… | 9-10 | | 财务报表附注…………………………………………… | 11-121 | 1 审 计 报 告 司农审字[2025]24008270037 号 博济医药科技股份有限公司全体股东: 一、审计意见 我们审计了博济医药科技股份有限公司（以下简称"博济医药"）财务报表，包 括 2024 年 12 月 31 日 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥138,861,747.84, a decrease of 17.06% compared to ¥167,424,382.67 in the same period last year[5] - The net profit attributable to shareholders was ¥3,900,579.72, down 76.38% from ¥16,513,092.18 year-on-year[5] - The basic earnings per share decreased to ¥0.0102, down 76.39% from ¥0.0432 in the same period last year[5] - The total comprehensive income for the period was ¥4,597,792.32, a decrease of 74.20% compared to ¥17,821,249.12 in the previous year[12] - Operating profit for the current period is CNY 3,903,457.70, a decline of 76.5% from CNY 16,614,526.52 in the previous period[26] - Net profit for the current period is CNY 3,843,087.85, down 77.0% from CNY 16,631,692.07 in the previous period[26] - The net profit attributable to the parent company was 3,900,579.72 yuan, a decrease from 16,513,092.18 yuan in the previous period, representing a decline of approximately 76.4%[27] - The total comprehensive income attributable to the parent company was 3,818,213.24 yuan, down from 17,076,703.66 yuan, indicating a decrease of about 77.7%[27] Cash Flow - The net cash flow from operating activities improved significantly to ¥8,828,695.62, compared to a negative cash flow of ¥15,764,811.36 in the previous year, representing a 156.00% increase[5] - Cash inflows from operating activities totaled 189,364,292.08 yuan, compared to 142,260,961.86 yuan in the prior period, reflecting an increase of approximately 33.2%[29] - Cash outflows from operating activities were 180,535,596.46 yuan, up from 158,025,773.22 yuan, marking an increase of about 14.3%[30] - The net cash flow from investing activities was -130,073,402.19 yuan, slightly improved from -153,727,515.94 yuan in the previous period[30] - The net cash flow from financing activities was 4,518,319.16 yuan, compared to a net outflow of 8,523,943.30 yuan in the prior period, indicating a turnaround[30] - The ending cash and cash equivalents balance was 151,790,383.34 yuan, down from 217,196,523.19 yuan, a decrease of approximately 30.1%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,491,435,459.66, reflecting a 2.82% increase from ¥1,450,592,225.50 at the end of the previous year[5] - Total current assets increased to CNY 823,520,451.16 from CNY 780,278,696.05, representing a growth of 5.0%[24] - Total non-current assets decreased slightly to CNY 667,915,008.50 from CNY 670,313,529.45, a decline of 0.4%[25] - Total liabilities increased to CNY 477,087,563.67 from CNY 448,838,881.46, an increase of 6.3%[25] - Total equity attributable to shareholders increased to CNY 985,275,784.42 from CNY 973,381,474.22, a growth of 1.0%[26] - Cash and cash equivalents decreased to CNY 153,365,620.33 from CNY 270,133,867.18, a decline of 43.2%[24] - Inventory increased to CNY 220,311,229.03 from CNY 189,485,440.64, an increase of 16.3%[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,693[15] - The largest shareholder, Wang Tingchun, holds 30.97% of the shares, amounting to 118,674,370 shares, with 89,005,777 shares pledged[16] - The top 10 shareholders hold a total of 89,005,777 shares, with no changes in the number of restricted shares during the period[19] - The total number of restricted shares at the end of the period was 105,113,676 shares, with 1,422,750 shares released during the period[19] - The company has a repurchase special account holding 2,667,000 shares, accounting for 0.70% of the total share capital[19] - The company’s major shareholder, Wang Tingchun, holds 29,668,593 shares, representing a significant portion of the total shares[18] - The company’s major shareholder, Zhao Lingli, holds 4,804,905 shares, indicating strong insider ownership[18] - The company has established a unified action relationship among certain shareholders, enhancing governance and decision-making[18] Research and Development - The company successfully passed the GLP certification review and received the new "Drug GLP Certification" with a total of 8 certification qualifications[20] - The company signed a technology transfer contract with Shaanxi Panlong Pharmaceutical Group, transferring the technology for "Glucosamine Sulfate Capsules" for a total fee of RMB 4.5 million[20] - The company's subsidiary, Huasheng Pharmaceutical, received approval for the listing application of "Sodium Sulfate" from the National Medical Products Administration[21] - In the first quarter of 2025, the company and its subsidiaries obtained seven invention patents from the National Intellectual Property Administration[21] Return on Equity - The weighted average return on equity was 0.40%, a decline of 1.32% from 1.72% in the previous year[5]

Financial Performance - Boji Medical Technology Co., Ltd. reported a revenue of RMB 500 million for the fiscal year 2024, representing a 20% increase compared to RMB 416.67 million in 2023[20]. - The company's operating revenue for 2024 reached ¥742,019,124.54, representing a 33.50% increase compared to ¥555,832,418.60 in 2023[5]. - The net profit attributable to shareholders for 2024 was ¥28,776,806.52, an 18.23% increase from ¥24,339,436.55 in 2023[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 92.71% to ¥19,304,628.89 from ¥10,017,432.95 in 2023[5]. - The company anticipates a net profit margin of 10% for 2024, compared to 8% in 2023, driven by operational efficiencies[20]. - The company reported a total investment of ¥44,125,000.00 during the reporting period, representing a substantial increase of 186.48% compared to ¥15,402,616.00 in the previous year[85]. - The company achieved a gross profit margin of 64.64% for the reported period[93]. Dividend Distribution - The company plans to distribute a cash dividend of 0.12 yuan per 10 shares to all shareholders, based on a total of 380,503,928 shares[8]. - The cash dividend represents 100% of the total distributable profit of RMB 28,776,806.52 for the year[154]. - For the year 2024, the company proposes a cash dividend of RMB 0.12 per 10 shares, with a total expected payout of RMB 4,566,047.14[156]. Business Expansion and Strategy - The company aims to expand its market presence by launching three new drug candidates in 2024, targeting a market size of approximately RMB 1 billion[20]. - The company is expanding its business into preclinical research and CDMO services, facing potential risks due to competition and lack of experience in these areas[8]. - The company is pursuing strategic acquisitions to bolster its capabilities, with a target of completing two acquisitions by the end of 2024[20]. - The company is focused on enhancing its digital health solutions, aiming for a 50% increase in user engagement through its online platforms in 2024[20]. - The company is committed to increasing its market share in the CDMO sector by improving order fulfillment capabilities and reducing delivery cycles, targeting rapid revenue growth from commercialized products[108]. Research and Development - The company has allocated RMB 100 million for research and development of new technologies and products in 2024, a 25% increase from RMB 80 million in 2023[20]. - The company has developed a one-stop service platform for preclinical research, significantly enhancing its capabilities in pharmacology and toxicology evaluations[49]. - The company has achieved GLP certification for its non-clinical evaluation services, covering various therapeutic areas, including cardiovascular and oncology drugs[52]. - The company is developing a long-acting nano-crystal technology platform aimed at improving drug delivery and reducing administration frequency, which is anticipated to create new business growth points[71]. - The company has completed the development of a new formulation of berberine for children, which is easier to administer[73]. Risk Management - The company acknowledges the risk of contract execution delays due to the complex nature of new drug development, which may lead to increased operational costs[5]. - The company emphasizes the importance of internal management and integration to mitigate risks associated with its expanding operational scale and business scope[8]. - The company recognizes the volatility of drug approval policies in China, which could impact its R&D investments and revenue[4]. - The company has established specific responsibility-sharing models in contracts to address potential delays and associated penalties[6]. Market Competition - The company faces increased market competition from domestic CRO companies, necessitating higher marketing and service standards[7]. - The Chinese CRO industry is expected to maintain a CAGR of 14%-16% from 2024 to 2026, with the market size projected to reach ¥478 billion in 2024[32]. - The company anticipates strong demand for outsourced clinical research services due to increasing complexity in drug development and stricter regulatory requirements[33]. Governance and Compliance - The company maintains independence from its controlling shareholder in terms of business, personnel, assets, and finance[118]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[114]. - The company has a dedicated financial department and independent financial decision-making capabilities[118]. - The company has not faced any disciplinary actions from regulatory bodies regarding internal control issues during the reporting period[117]. - The company ensures timely and accurate information disclosure through designated platforms and publications[115]. Environmental Responsibility - The company has obtained a wastewater discharge permit valid until October 31, 2027[187]. - The wastewater treatment facility has a capacity of 120m³/d and employs a "flocculation sedimentation + iron-carbon micro-electrolysis" process[189]. - The company reported a total wastewater discharge of 0.33 tons for CODcr, which is below the regulatory limit of 0.412 tons per annum[188]. - The company has established solid waste management records to ensure compliance with environmental regulations[192]. Employee Management - The company had a total of 1,169 employees at the end of the reporting period, with 888 being technical personnel, representing approximately 76% of the workforce[148]. - The company has a comprehensive training system that includes various training categories, ensuring continuous development of employee skills and capabilities[151]. - The company has implemented a differentiated compensation policy based on department, position, and job nature, aiming for performance-oriented salary management[150]. Future Outlook - The company plans to continue expanding its market presence and enhancing product development strategies[1]. - Future outlook includes potential adjustments in management structure following the resignation of certain executives in 2025[140]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[134].

博济医药（300404）公告，2025年第一季度营业收入1.39亿元，同比下降17.06%。净利润390.06万元， 同比下降76.38%。 ...

2024 年 8 月 23 日，博济医药科技股份有限公司（以下简称"公司"）召开 第五届董事会第十次会议和第五届监事会第十次会议，审议通过了《关于使用暂 时闲置募集资金进行现金管理的议案》，同意公司及子公司使用不超过人民币 0.6 亿元（含）闲置募集资金进行现金管理，有效期自董事会审议通过之日起 12 个 月内，在前述额度和期限范围内可循环滚动使用。具体内容详见公司于 2024 年 8 月 27 日在巨潮资讯网（http://www.cninfo.com.cn/）上发布的《关于使用暂时闲 置募集资金进行现金管理的公告》（公告编号：2024-087）。 近日，公司全资子公司深圳博瑞医药科技有限公司（以下简称"深圳博瑞"） 在授权范围内使用闲置募集资金购买的理财产品已到期赎回。现就有关进展情况 公告如下： 证券代码：300404 证券简称：博济医药 公告编号：2025-018 博济医药科技股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | | | 中国工商银 | 中国工商银行挂钩汇率法 | | | ...